These studies support the emerging concept that UCP-2 (and possibly UCP-3) expression in human islets may contribute to decreased GSIS in patients with type-2 diabetes who are exposed to chronically increased glucose levels. The gene discussed is UCP3; the disease is type 2 diabetes mellitus.